FBL18 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that targets multiple signaling pathways, including the PI3K/AKT/mTOR pathway. Inhibition of this pathway indirectly down-regulates FBL18 expression by disrupting downstream signaling cascades involved in its regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinase (PI3K), a key enzyme in the PI3K/AKT/mTOR pathway. By blocking PI3K activity, Wortmannin disrupts downstream signaling events that regulate FBL18 expression, resulting in its down-regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), which plays a crucial role in the PI3K/AKT/mTOR pathway. Inhibition of PI3K by LY294002 leads to the suppression of downstream signaling cascades that control FBL18 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTORC1 complex, a downstream effector of the PI3K/AKT/mTOR pathway. By blocking mTORC1 activity, Rapamycin disrupts signaling events that regulate FBL18 expression, resulting in its down-regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK, a signaling kinase involved in various cellular processes. Inhibition of p38 MAPK by SB203580 leads to the suppression of downstream signaling pathways that regulate FBL18 expression, resulting in its inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), a member of the MAPK signaling pathway. By blocking JNK activity, SP600125 disrupts signaling cascades that regulate FBL18 expression, leading to its down-regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1 and MEK2, upstream kinases in the MAPK/ERK signaling pathway. Inhibition of MEK1/2 by U0126 disrupts downstream signaling events that control FBL18 expression, resulting in its down-regulation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a potent and selective inhibitor of MEK1 and MEK2, key kinases in the MAPK/ERK signaling pathway. Inhibition of MEK1/2 by PD98059 leads to the suppression of downstream signaling cascades that regulate FBL18 expression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases, including RAF kinases involved in the MAPK/ERK signaling pathway. By blocking RAF kinase activity, Sorafenib disrupts downstream signaling events that regulate FBL18 expression, leading to its down-regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a potent inhibitor of multiple tyrosine kinases, including SRC family kinases. Inhibition of SRC kinases by Dasatinib disrupts downstream signaling cascades that regulate FBL18 expression, resulting in its down-regulation. | ||||||